Analysts were quick to rank Biogen $BIIB a hold or sell. Some dared call the stock a buy. Per tipranks, use the success rate to check which analyst to take seriously. Tipranks /5 Rating Price Target Analyst Firm Success Rate 2.1 Hold $236 Guggenheim 49% 4.8 Hold $250 BMO Capital 54% 4 Hold $250 Jefferies 51% 3.6 Hold $242 UBS 43% 4.5 Sell $210 Morgan Stanley 60% 4.5 Hold $250 Cantor Fitzgerald 49% 4.1 Hold $250.00 Barclays 56% 4.8 Hold $233 Stifel Nicolaus 58% 1.9 Hold $244 J.P. Morgan 41% 4.7 Hold $275 Merrill Lynch 73% 4.4 Hold $286 Goldman Sachs 62% 4.5 Buy $320 Nomura 50% 4.6 Buy $275.00 Cowen & Co. 51% 4.2 Hold $230 Citigroup 53% 4.5 Hold $250 Robert W. Baird 56% 1.3 Hold $275 Canaccord Genuity 39% 4.8 Buy $280 Piper Jaffray 58% 2.1 Hold $325 Guggenheim 49% $GS at a 4.4 rating has a hold and $286 PT: $BIIB, Biogen Inc. / H1 No chart action or valuation will be of use at this time to set a PT on Biogen. The Value Stock group is neutral for now.Biotech picks $XBIT and $DERM are March's Picks: $DERM, Dermira, Inc. / H1 XBIT did well for subscribers and members (requires subscription): $XBIT, XBiotech Inc. / H1